GlassScriptPhysician profile
Cherylee Wj Chang
NPI 1023170271
$826.50
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $469 · 2020: $38.84 · 2021: $97.60 · 2022: $96.50 · 2023: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $125.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Portola Pharmaceuticals, LLC | $214.30 | 2019 | |
| Alexion Pharmaceuticals, INC. | $194.10 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2023 | |
| Ucb, INC. | $122.92 | 2019 | |
| Convatec INC. | $49.25 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $44.95 | 2019 | |
| Pfizer INC. | $43.14 | 2019-2020 | |
| Covidien LP | $20.41 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $12.43 | 2019 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cherylee Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.